论文部分内容阅读
医药部门权威人士近日指出,我国医药经济结构性矛盾十分突出,如不尽快加以解决,势必对医药行业的持续稳定发展产生不利影响。 首先,医药产业结构不合理。目前,我国制剂工业落后于原料药工业,企业生产达到药品生产管理规范(GMP)要求的不到10％,能够打入国际市场的制剂品种寥寥无几;医疗器械工业落后于化学药品工业;制药机械及包装材料工业发展缓慢,制约了整个制药工业发展。其二,企业组织结构不合理。至1995年,全国制药企业由80年的800家激增到5655家,而其中90％以上是小企业,生产能力过剩的问题非常严重。由于各地在局
Authorities of the pharmaceutical sector recently pointed out that the structural contradictions in China’s pharmaceutical economy are very prominent. If it is not resolved as soon as possible, it will certainly have an adverse impact on the sustained and stable development of the pharmaceutical industry. First of all, the pharmaceutical industry structure is irrational. At present, China’s pharmaceutical industry lags behind the raw material pharmaceutical industry, and its production reaches less than 10% of the GMP requirements. There are few preparations that can enter the international market; the medical device industry lags behind the chemical industry; pharmaceutical machinery And the slow development of packaging materials industry has restricted the development of the entire pharmaceutical industry. Second, the organizational structure of the company is irrational. By 1995, the number of pharmaceutical companies across the country had surged from 800 in 80 years to 5,655, of which more than 90% were small businesses, and the issue of excess production capacity was very serious. Because of the various places in the bureau